Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (EDIT) is a healthcare company (biotechnology) based in the United States. The share price is $1.88, up 0.53% on the day, which values the company at $290.16M. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$1.88+0.53% today
Market value
$290.16M
Funk Score
38/100
Against its own history
Well below its usual priceusual price $7.55
200-week average
$4.6760% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Editas Medicine, Inc. in more detail

EDIT trades at -2.6× next year's expected earnings, 5.8× sales. Measured against its own history, the price is 75% below what its usual multiples would imply ($7.55) — well below its usual price. It sits 60% below its 200-week average of $4.67.

Over the last five fiscal years Editas Medicine, Inc. has compounded revenue -14.9% a year. Its Funk Score is 38 out of 100 (financial strength 3.1, profitability 2.5, growth 4.7, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold EDIT, including Peter Kolchinsky (0.3% of the portfolio).

Superinvestors holding EDIT

1 of the investors tracked here report a position in their latest 13F filing.

Editas Medicine, Inc. (EDIT): questions and answers

What is Editas Medicine, Inc.'s market cap?

Editas Medicine, Inc. is valued at $290.16M at a share price of $1.88.

Is EDIT overvalued or undervalued?

Against its own history, EDIT is well below its usual price: the price is 75% below the $7.55 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is EDIT above its 200-week moving average?

No. EDIT is 59.7% below its 200-week average of $4.67. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Editas Medicine, Inc. growing?

Over the last five fiscal years Editas Medicine, Inc.'s revenue grew -14.9% a year.

Does EDIT pay a dividend?

Editas Medicine, Inc. does not currently pay a regular dividend.

Which famous investors own EDIT?

In their latest quarterly filings, Peter Kolchinsky (0.3% of the portfolio) hold EDIT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Editas Medicine, Inc. (EDIT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/EDIT

Underlying data: Yahoo Finance; company filings with the SEC.